According to the NIA-AA research criteria framework, our seven participants with abnormal amyloid (A+) but normal CSF p-tau (T−) and no tau PET available are most accurately described as consistent with Alzheimer’s neuropathologic change rather than definitive progressive dysexecutive syndrome with Alzheimer’s disease. This evidence concerns the gene MAPT and Alzheimer disease.